CNSP Earnings CNS Pharmaceuticals, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -7.30 | 2026-05-14 | 10-Q |
| FY 2025 | 2025-12-31 | -35.75 | 2026-03-31 | 10-K |
| Q3 2025 | 2025-09-30 | -25.60 | 2025-11-14 | 10-Q |
| Q2 2025 | 2025-06-30 | -22.35 | 2025-08-14 | 10-Q |
| Q1 2026 | 2025-03-31 | -18.93 | 2026-05-14 | 10-Q |
| FY 2025 | 2024-12-31 | -466.89 | 2026-03-31 | 10-K |
| Q3 2025 | 2024-09-30 | -927.76 | 2025-11-14 | 10-Q |
| Q2 2025 | 2024-06-30 | -13294.31 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -1020.48 | 2025-05-15 | 10-Q |
| FY 2024 | 2023-12-31 | -12509.11 | 2025-03-31 | 10-K |
| Q3 2024 | 2023-09-30 | -202.48 | 2024-11-14 | 10-Q |
| Q2 2024 | 2023-06-30 | -154.70 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -2.59 | 2024-05-15 | 10-Q |
| FY 2023 | 2022-12-31 | -11.22 | 2024-04-01 | 10-K |
| Q3 2023 | 2022-09-30 | -7.67 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -5.11 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -2.44 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -16.50 | 2023-03-31 | 10-K |
| Q3 2022 | 2021-09-30 | -0.43 | 2022-11-10 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.30 | 2022-08-12 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.